PGK1 and Familial prostate cancer: Further, PGK1/G6PD-marked hypermetabolic CTCs (GM+CTCs, i.e. DAPI+CD45−PGK1/G6PD+ cells) potentially represent a more accurate marker than EMT-CTCs for the diagnosis of metastasis in prostate cancer patients (109).